Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lantern Pharma, Inc. (LTRN)
NASDAQ:LTRN
Holding LTRN?
Track your performance easily
LTRN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.79 - $11.99
Previous Close$3.15
Volume39.34K
Average Volume (3M)53.77K
Market Cap
$33.92M
Enterprise Value$6.16M
Total Cash (Recent Filing)$28.05M
Total Debt (Recent Filing)$291.24K
Price to Earnings (P/E)―
Beta2.60
Next Earnings
Mar 06, 2025EPS Estimate
-$0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.77
Shares Outstanding10,784,725
10 Day Avg. Volume74,553
30 Day Avg. Volume53,768
Standard Deviation0.21
R-Squared0.13
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.27
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.74
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Lantern Pharma News
PremiumCompany Announcements
Lantern Pharma Discusses Q3 Financial Results Webinar
PremiumCompany Announcements
Lantern Pharma Advances AI-Driven Cancer Therapies
PremiumCompany Announcements
Lantern Pharma Q2 Results and LP-300 Clinical Trial UpdateOwnership Overview
22.88% Insiders
4.17% Mutual Funds
3.64% Other Institutional Investors
65.55% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
LTRN FAQ
What was Lantern Pharma, Inc.’s price range in the past 12 months?
Lantern Pharma, Inc. lowest stock price was $2.79 and its highest was $11.99 in the past 12 months.
What is Lantern Pharma, Inc.’s market cap?
Currently, no data Available
When is Lantern Pharma, Inc.’s upcoming earnings report date?
Lantern Pharma, Inc.’s upcoming earnings report date is Mar 06, 2025 which is in 74 days.
How were Lantern Pharma, Inc.’s earnings last quarter?
Lantern Pharma, Inc. released its earnings results on Nov 07, 2024. The company reported -$0.42 earnings per share for the quarter, beating the consensus estimate of -$0.56 by $0.14.
Is Lantern Pharma, Inc. overvalued?
According to Wall Street analysts Lantern Pharma, Inc.’s price is currently Overvalued.
Does Lantern Pharma, Inc. pay dividends?
Lantern Pharma, Inc. does not currently pay dividends.
What is Lantern Pharma, Inc.’s EPS estimate?
Lantern Pharma, Inc.’s EPS estimate is -$0.51.
How many shares outstanding does Lantern Pharma, Inc. have?
Lantern Pharma, Inc. has 10,784,725 shares outstanding.
What happened to Lantern Pharma, Inc.’s price movement after its last earnings report?
Lantern Pharma, Inc. reported an EPS of -$0.42 in its last earnings report, beating expectations of -$0.56. Following the earnings report the stock price went up 12.281%.
Which hedge fund is a major shareholder of Lantern Pharma, Inc.?
Among the largest hedge funds holding Lantern Pharma, Inc.’s share is Fisher Asset Management LLC. It holds Lantern Pharma, Inc.’s shares valued at N/A.
---
Lantern Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 10.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 9.8%
Last 30 Days ▼ 9.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.94%
12-Months-Change
Fundamentals
Return on Equity
-53.03%
Trailing 12-Months
Asset Growth
-36.59%
Trailing 12-Months
Company Description
Lantern Pharma, Inc.
Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline of development programs involves three small molecule drug candidates namely LP-100, LP-184, and LP-300.
---
LTRN Company Deck
---
LTRN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in AI-driven drug development, regulatory achievements, and strategic trial expansions, while noting increased financial losses and R&D expenses. The positive advancements and strategic positioning outweigh the financial challenges.Read More>---
LTRN Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Adaptimmune Therapeutics
―
Cyclerion Therapeutics
―
Gritstone bio
―
Karyopharm Therapeutics
―
---